158 related articles for article (PubMed ID: 15816210)
1. Comparison of in vitro susceptibilities to levofloxacin and ciprofloxacin with Pseudomonas aeruginosa and Stenotrophomonas maltophilia isolated from cystic fibrosis patients in Northern Ireland.
McKnight AJ; Shaw A; Goldsmith CE; Clarke L; Millar BC; McCaughan J; Elborn JS; Reid A; Moore JE
Br J Biomed Sci; 2005; 62(1):30-2. PubMed ID: 15816210
[No Abstract] [Full Text] [Related]
2. Levofloxacin, a broad spectrum anti-infective: from Streptococcus pneumoniae to Pseudomonas aeruginosa.
Schito AM; Schito GC
J Chemother; 2004 Apr; 16 Suppl 2():3-7. PubMed ID: 15255554
[No Abstract] [Full Text] [Related]
3. Reclassification of CLSI criteria for ciprofloxacin and levofloxacin susceptibility against Pseudomonas aeruginosa: Implications for patients with cystic fibrosis (CF).
Millar BC; Malnarcic CM; McCaughan J; Moore JE
Clin Respir J; 2020 Jan; 14(1):64-68. PubMed ID: 31663261
[No Abstract] [Full Text] [Related]
4. The Effects of Antibiotic Combination Treatments on Pseudomonas aeruginosa Tolerance Evolution and Coexistence with Stenotrophomonas maltophilia.
Law JP; Wood AJ; Friman VP
Microbiol Spectr; 2022 Dec; 10(6):e0184222. PubMed ID: 36453898
[TBL] [Abstract][Full Text] [Related]
5. Biofilm compared to conventional antimicrobial susceptibility of Stenotrophomonas maltophilia Isolates from cystic fibrosis patients.
Wu K; Yau YC; Matukas L; Waters V
Antimicrob Agents Chemother; 2013 Mar; 57(3):1546-8. PubMed ID: 23295930
[TBL] [Abstract][Full Text] [Related]
6. In vivo oral efficacy of levofloxacin for treatment of systemic Pseudomonas aeruginosa infections in a murine model of septicemia.
Yagel SK; Barrett JF; Amaratunga DJ; Frosco MB
Antimicrob Agents Chemother; 1996 Dec; 40(12):2894-7. PubMed ID: 9124863
[TBL] [Abstract][Full Text] [Related]
7. Investigation into the selection frequency of resistant mutants and the bacterial kill rate by levofloxacin and ciprofloxacin in non-mucoid Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Gillespie T; Masterton RG
Int J Antimicrob Agents; 2002 May; 19(5):377-82. PubMed ID: 12007845
[TBL] [Abstract][Full Text] [Related]
8. Genotype and antibiotic susceptibility patterns of Pseudomonas aeruginosa and Stenotrophomonas maltophilia isolated from cystic fibrosis patients.
Nazik H; Ongen B; Erturan Z; Salcioğlu M
Jpn J Infect Dis; 2007 May; 60(2-3):82-6. PubMed ID: 17515637
[TBL] [Abstract][Full Text] [Related]
9. What have we learned about early treatment of Pseudomonas aeruginosa infection in infants and children with cystic fibrosis?
Saiman L; Cohen MB
Arch Pediatr Adolesc Med; 2011 Sep; 165(9):867-8. PubMed ID: 21893653
[No Abstract] [Full Text] [Related]
10. Comparative Activity of Ciprofloxacin, Levofloxacin and Moxifloxacin against Klebsiella pneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia Assessed by Minimum Inhibitory Concentrations and Time-Kill Studies.
Grillon A; Schramm F; Kleinberg M; Jehl F
PLoS One; 2016; 11(6):e0156690. PubMed ID: 27257956
[TBL] [Abstract][Full Text] [Related]
11. Coordinate hyperproduction of SmeZ and SmeJK efflux pumps extends drug resistance in Stenotrophomonas maltophilia.
Gould VC; Okazaki A; Avison MB
Antimicrob Agents Chemother; 2013 Jan; 57(1):655-7. PubMed ID: 23147729
[TBL] [Abstract][Full Text] [Related]
12. Comparative activities of isepamicin, amikacin, cefepime, and ciprofloxacin alone or in combination with other antibiotics against Stenotrophomonas maltophilia.
Tripodi MF; Andreana A; Sarnataro G; Ragone E; Adinolfi LE; Utili R
Eur J Clin Microbiol Infect Dis; 2001 Jan; 20(1):73-5. PubMed ID: 11245333
[No Abstract] [Full Text] [Related]
13. Levofloxacin in vitro activity and time-kill evaluation of Stenotrophomonas maltophilia clinical isolates.
Bonfiglio G; Cascone C; Azzarelli C; Cafiso V; Marchetti F; Stefani S
J Antimicrob Chemother; 2000 Jan; 45(1):115-7. PubMed ID: 10629022
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of β-lactams in combination with avibactam against multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Achromobacter xylosoxidans isolates from patients with cystic fibrosis.
Mathy V; Grohs P; Compain F
J Med Microbiol; 2018 Sep; 67(9):1217-1220. PubMed ID: 30016231
[TBL] [Abstract][Full Text] [Related]
15. Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa.
Roveta S; Schito AM; Marchese A; Schito GC
Int J Antimicrob Agents; 2005 Nov; 26(5):366-72. PubMed ID: 16216467
[TBL] [Abstract][Full Text] [Related]
16. Increasing Incidence of Multidrug Resistance Among Cystic Fibrosis Respiratory Bacterial Isolates.
Rutter WC; Burgess DR; Burgess DS
Microb Drug Resist; 2017 Jan; 23(1):51-55. PubMed ID: 27326758
[TBL] [Abstract][Full Text] [Related]
17. Activity of levofloxacin and ciprofloxacin on biofilms and planktonic cells of Stenotrophomonas maltophilia isolates from patients with device-associated infections.
Passerini de Rossi B; García C; Calenda M; Vay C; Franco M
Int J Antimicrob Agents; 2009 Sep; 34(3):260-4. PubMed ID: 19362452
[TBL] [Abstract][Full Text] [Related]
18. Aerosolized amikacin and oral clarithromycin to eradicate Mycobacterium abscessus in a patient with cystic fibrosis: an 8-year follow-up.
Colin AA; Ali-Dinar T
Pediatr Pulmonol; 2010 Jun; 45(6):626-7. PubMed ID: 20503290
[No Abstract] [Full Text] [Related]
19. The efficacy and safety of ciprofloxacin and ofloxacin in chronic Pseudomonas aeruginosa infection in cystic fibrosis.
Jensen T; Pedersen SS; Nielsen CH; Høiby N; Koch C
J Antimicrob Chemother; 1987 Oct; 20(4):585-94. PubMed ID: 3479420
[TBL] [Abstract][Full Text] [Related]
20. Role of anti-pseudomonal antibiotics in the emergence of Stenotrophomonas maltophilia in cystic fibrosis patients.
Denton M; Todd NJ; Littlewood JM
Eur J Clin Microbiol Infect Dis; 1996 May; 15(5):402-5. PubMed ID: 8793400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
